Insmed

Insmed R&D per Employee

The R&D Spending per Employee of Insmed (INSM) as of Oct 10, 2026 is 463,397.24 USD. In the previous year, R&D Spending per Employee was 359,595.55 USD — a change of 28.87% (higher).

R&D per Employee

463,397.24USD

YoY

28.87%

Last updated:

R&D Spending per Employee of Insmed is 2025 463,397.24 USD. R&D Spending per Employee of Insmed was 2024 359,595.55 USD. It decreases by 28.87% higher compared to the previous year.

The Insmed R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
87,309.50 USD
Jan 1, 2019
79,153.25 USD
Jan 1, 2020
108,868.39 USD
Jan 1, 2021
163,908.65 USD
Jan 1, 2022
238,893.03 USD
Jan 1, 2023
343,155.65 USD
Jan 1, 2024
359,595.55 USD
Jan 1, 2025
463,397.24 USD
The Insmed R&D per Employee history
YEARR&D per EmployeeYoY
463,397.24USD+28.87%
359,595.55USD+4.79%
343,155.65USD+43.64%
238,893.03USD+45.75%
163,908.65USD+50.56%
108,868.39USD+37.54%
79,153.25USD-9.34%
87,309.50USD+32.38%
65,954.93USD-10.57%
73,750.60USD+65.22%
44,637.62USD+31.95%
33,829.33USD—
Access this data via the Eulerpool API

Insmed Stock analysis

What does Insmed do? Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insmed stock

R&D Spending per Employee of Insmed is 463,397.24 USD in 2025.

R&D Spending per Employee of Insmed changed from 359,595.55 USD to 463,397.24 USD, representing a 28.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Insmed since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Insmed historically and in real time.

Access this data via the Eulerpool API

Workforce — Insmed

All Key Metrics — Insmed